At one point in time, Zantac was the number one selling drug in the world. In 1988, the heartburn and acid reflux medication was sold to hundreds of millions. Fast forward 30 years and Zantac is now mired in cancer risk lawsuits stemming from the discovery of NDMA in its branded and generic (ranitidine) form.
That millions of people now face the possibility they may develop certain cancers after using Zantac is startling. On top of that, firms filing Zantac lawsuits are finding its producers may have known about the NDMA contamination since the 1980s and that they deceptively marketed the drug.
A third risk lurks in the shadows. Among these millions, another cohort shares a group of characteristics that strengthens the odds they are most likely to develop cancer after taking Zantac. If you fall into one, or any of the following 8 categories, you might be a member.
1. You Are Overweight
MedPage reports those who took H2 blockers such as ranitidine and had cancer, also had a history of being overweight when compared with those who did not take the heartburn and acid reflux drug.
2. You Smoke And/Or Drink Alcohol
MedPage presented similar findings for those who took H2 blockers, drank and smoked. Seventy-five percent of persons who took Zantac and who had cancer were also smokers.
3. You Have Pre-existing/Co-existing Lifestyle Disease
While the report did not mention a specific percentage, it alluded to those with “family histories”, who overall presented higher numbers of cancer cases in association with taking Zantac.
4. You Used Zantac Or One Of Its Generics Frequently
If you had significant trouble with heartburn or acid reflux, you likely turned to Zantac for relief more often than the average person. What you could not have known was that each time, you unintentionally increased NMDA levels in your system increasing your risk for cancer.
5. You Used Zantac Or One Of Its Generics Over A Long period
Someone who took Zantac for occasional stomach troubles will present a significantly lower risk for developing cancer than someone who took it at maximum strength, multiple times a day, for decades.
6. You Took Higher Doses Of Zantac Or One Of Its Generics
Zantac was available in several formulations. The stronger the OTC version you bought, the more NDMA compounds you were likely to have been exposed to.
7. You Took Zantac That Had Aged
In a December 2020 paper, Gerald McGwin said NDMA formation might have been the result of ranitidine breaking down over time. Older samples of the drug showed high amounts of the carcinogen when tested against less aged samples.
8. Your Age
The MedPage report shows that 34 percent of the sample of H2 blocker users who had cancer were over the age of 65.
It should be noted that lifestyle diseases, old age, smoking and drinking and obesity by themselves carry an elevated risk for the kinds of cancers that Zantac is said to cause. When a person wishes to file suit, establishing what brought about cancer could sometimes be difficult.
What should you do?
This is why you need a qualified team of legal professionals at your side. Drug Guardians is working in partnership with others across the country to bring class action litigation against manufacturers of ranitidine.
We believe they brought a drug they knew to be faulty to the market and failed to warn consumers about the risks of NDMA. If you, or a loved one, are now sick because of this deliberate and reckless endangerment on their part, you are not alone and help is available.
We offer a free consultation to see how we can assist. From there, we help with gathering evidence and medical records for your claim and establishing the link between your cancer and Zantac use.
From all indications, it does not appear as though ranitidine manufacturers intend to settle cases soon and you should be prepared for a lengthy wait to have your day in court. One of the first lawsuits against manufacturers is seven years old.
Is it worth it?
A better question is what do you have to lose? Settlements have run from $100,000 – $250,000 and we are not paid until you are.